| Dr Ellen J Halverson, MD | |
|
2250 S Woodworth Loop, Suite 202, Palmer, AK 99645-7412 | |
| (907) 761-5800 | |
| (907) 761-5801 |
| Full Name | Dr Ellen J Halverson |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 37 Years |
| Location | 2250 S Woodworth Loop, Palmer, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467478164 | NPI | - | NPPES |
| 1010614 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 4152 (Alaska) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Washington | 8628965910 | 41 |
News Archive
When T cells encounter an antigen, they proliferate and produce various types of daughter cells. A team at the Technical University of Munich has now refuted the prevailing hypothesis that this immune response is largely predetermined by the individual structure of the T cell receptor.
QRxPharma announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission.
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.
People with type 2 diabetes are not consuming sufficiently healthy diets and could benefit from ongoing nutritional education and counseling, according to a new study by researchers at Wake Forest University School of Medicine and colleagues.
› Verified 8 days ago
| Entity Name | Providence Health & Services Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538254347 PECOS PAC ID: 8628965910 Enrollment ID: O20040302000372 |
News Archive
When T cells encounter an antigen, they proliferate and produce various types of daughter cells. A team at the Technical University of Munich has now refuted the prevailing hypothesis that this immune response is largely predetermined by the individual structure of the T cell receptor.
QRxPharma announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission.
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.
People with type 2 diabetes are not consuming sufficiently healthy diets and could benefit from ongoing nutritional education and counseling, according to a new study by researchers at Wake Forest University School of Medicine and colleagues.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ellen J Halverson, MD Po Box 4105, Portland, OR 97208-4105 Ph: (866) 907-1068 | Dr Ellen J Halverson, MD 2250 S Woodworth Loop, Suite 202, Palmer, AK 99645-7412 Ph: (907) 761-5800 |
News Archive
When T cells encounter an antigen, they proliferate and produce various types of daughter cells. A team at the Technical University of Munich has now refuted the prevailing hypothesis that this immune response is largely predetermined by the individual structure of the T cell receptor.
QRxPharma announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission.
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.
People with type 2 diabetes are not consuming sufficiently healthy diets and could benefit from ongoing nutritional education and counseling, according to a new study by researchers at Wake Forest University School of Medicine and colleagues.
› Verified 8 days ago
Ryah Mckinley, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2500 S Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6565 Fax: 907-961-6568 | |
Mrs. Jamie Danielle Alexander, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: Mat-su Regional Medical Center, 2500 S. Woodworth Loop, Palmer, AK 99645 Phone: 907-861-6000 | |
Jane Margaret Larouche, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2250 S Woodworth Loop Ste 202, Palmer, AK 99645 Phone: 907-761-5800 Fax: 907-761-5801 |